In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Sean Tucker Biography and Net Worth

SVP of Vaxart

Dr. Tucker is the Founder of Vaxart and has served as our Chief Scientific Officer since February 2010. From March 2004 to February 2010, Dr. Tucker served as our Vice President of Research and Director of Immunology. Prior to this, Dr. Tucker held numerous scientific and engineering roles at various biotechnology companies. Dr. Tucker received a B.S. in chemical engineering from the University of Washington, an M.S. in chemical engineering from the University of California, Berkeley, and a Ph.D. in immunology from the University of Washington.

What is Sean Tucker's net worth?: The estimated net worth of Sean Tucker is at least $209.79 as of August 10th, 2021. Dr. Tucker owns 333 shares of Vaxart stock worth more than $210 as of November 14th. This net worth approximation does not reflect any other assets that Dr. Tucker may own. Additionally, Dr. Tucker receives a salary of $561,100.00 as SVP at Vaxart. Learn More about Sean Tucker's net worth.
How old is Sean Tucker?: Dr. Tucker is currently 56 years old. There are 5 older executives and no younger executives at Vaxart. The oldest executive at Vaxart is Mr. Edward B. Berg, Senior VP & General Counsel, who is 60 years old. Learn More on Sean Tucker's age.
What is Sean Tucker's salary?: As the SVP of Vaxart, Inc., Dr. Tucker earns $561,100.00 per year. The highest earning executive at Vaxart is Dr. James F. Cummings M.D., Chief Medical Officer, who commands a salary of $594,500.00 per year. Learn More on Sean Tucker's salary.
How do I contact Sean Tucker?: The corporate mailing address for Dr. Tucker and other Vaxart executives is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. Vaxart can also be reached via phone at (650) 550-3500 and via email at [email protected]. Learn More on Sean Tucker's contact information.
Has Sean Tucker been buying or selling shares of Vaxart?: Sean Tucker has not been actively trading shares of Vaxart during the last quarter. Most recently, Sean Tucker sold 4,172 shares of the business's stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $10.20, for a transaction totalling $42,554.40. Following the completion of the sale, the senior vice president now directly owns 333 shares of the company's stock, valued at $3,396.60. Learn More on Sean Tucker's trading history.
Who are Vaxart's active insiders?: Vaxart's insider roster includes Margaret Echerd (SVP), Wouter Latour (Director), and Sean Tucker (SVP). Learn More on Vaxart's active insiders.
Are insiders buying or selling shares of Vaxart?: During the last year, Vaxart insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $13,600.00. The most recent insider tranaction occured on June, 18th when Director W. Mark Watson bought 20,000 shares worth more than $13,600.00. Insiders at Vaxart own 2.6% of the company. Learn More about insider trades at Vaxart.
Information on this page was last updated on 6/18/2024.

Sean Tucker Insider Trading History at Vaxart

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2021	Sell	4,172	$10.20	$42,554.40	333
4/11/2019	Buy	27,273	$1.10	$30,000.30

Sean Tucker Buying and Selling Activity at Vaxart

Vaxart Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Today's Range

Now: $0.63

$0.63

$0.69

50 Day Range

MA: $0.82

$0.69

$0.99

2 Week Range

Now: $0.63

$0.52

$1.54

Volume

2,492,972 shs

Average Volume

2,487,540 shs

Market Capitalization

$111.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Sean Tucker Biography and Net Worth

What is Sean Tucker's net worth?

How old is Sean Tucker?

What is Sean Tucker's salary?

How do I contact Sean Tucker?

Has Sean Tucker been buying or selling shares of Vaxart?

Who are Vaxart's active insiders?

Are insiders buying or selling shares of Vaxart?